• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
  • CONTACT
ProAxsis to showcase ProteaseTag® abstracts at 2017 North American Cystic Fibrosis Conference
Share
ProteaseTag®

ProAxsis to showcase ProteaseTag® abstracts at 2017 North American Cystic Fibrosis Conference

October 30, 2017
-
Posted by Webmaster

ProAxsis will be presenting further data on its ProteaseTag® technology, at the North American Cystic Fibrosis Conference, which takes place between November 1st – 5th in Indianapolis. Dr Charlene Robb will be presenting a poster entitled “Do sputum storage conditions impact on the quantification of active neutrophil elastase, interleukin-8, interleukin-6 and tumour necrosis factor-α?” on Thursday November 2nd between 11.15am and 1.45pm (Poster Number 288).

In addition, the team at the Royal Brompton Hospital in London, one of the largest CF expert centres in Europe, will be presenting the first data on the use of the ProteaseTag® Active NE Immunoassay to measure active neutrophil elastase in exhaled breath condensate:

Active Neutrophil Elastase can be detected in Exhaled Breath Condensate in patients with Cystic Fibrosis

C74-ADVANCES IN TRANSLATIONAL COPD

Thematic Poster Session

TUESDAY, MAY 23, 2017

9:15 AM – 4:15 PM

Jane Davies, Professor in Paediatric Respirology & Experimental Medicine at the National Heart and Lung Institute and an Honorary Consultant in Paediatric Respiratory Medicine at the Royal Brompton & Harefield NHS Foundation Trust, said ”To our knowledge this is the first study to report NE in EBC in CF patients; whilst the method requires further optimisation, we believe this could be a promising avenue for monitoring of patients at early stages of disease, such as children.”

Dr David Ribeiro, CEO of ProAxsis, said: “This is the 31st annual NACF Conference, which brings together scientists, clinicians and caregivers from around the world to discuss and share ideas on the latest advances in CF research. The work by Dr Robb and colleagues provides further data for researchers conducting clinical trials worldwide who need to collect, transport and analyse sputum samples for inflammatory biomarkers such as active neutrophil elastase. The 19-patient study conducted at the Royal Brompton Hospital opens up the possibility of utilising the ProAxsis technology for airway monitoring in patients unable to expectorate sputum. We believe these latest findings on our ProteaseTag® technology will be of great interest to the CF community. ”

To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact info@proaxsis.com.

October 30, 2017

Related News

Other posts that you should not miss.
Conferences, Neutrophil Elastase Immunoassay, News, ProteaseTag®

ProAxsis’ ProteaseTag® NE Immunoassay highlighted at BTS 2016

December 8, 2016
-
Posted by Webmaster

ProAxsis (www.proaxsis.com) was delighted to observe that measuring active neutrophil elastase (NE) by its ProteaseTag® Active NE Immunoassay …

Read More
December 8, 2016
Posted by Webmaster
Announcements, ProteaseTag®

ProAxsis technology highlighted in AJRCCM editorial

May 17, 2017
-
Posted by Webmaster

ProAxsis Ltd is delighted to observe that its ProteaseTag® Active Neutrophil Elastase Immunoassay is prominently featured in the …

Read More
May 17, 2017
Posted by Webmaster
News, ProteaseTag®

ProAxsis abstracts at 2017 American Thoracic Society Conference

May 5, 2017
-
Posted by Webmaster

ProAxsis will be presenting further data on its ProteaseTag® technology, at the American Thoracic Society Conference, which takes …

Read More
May 5, 2017
Posted by Webmaster
← PREVIOUS POST
ProAxsis provides update on commercialisation progress
NEXT POST →
ProAxsis to test ProteaseTag® Technology in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease at National Jewish Health
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test
    June 7, 2021

    ProAxsis Limited (www.proaxsis.com), the Belfast-based respiratory diagnostics company, is delighted to announce it …

  • ProAxsis Ltd CEO Update Report – May 2021
    May 21, 2021

    Introduction In parallel with the release of the company’s 2020 financial statements, I …

  • ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases
    February 21, 2021

    ProAxsis (www.proaxsis.com), the Belfast-based diagnostics company, and a collaboration of the University of …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • May 17, 2022
    Belfast Telegraph Awards
  • May 16, 2022
    ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test
  • January 31, 2022
    ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife
Copyright © 2016-2021 - ProAxsis - All rights reserved. 
ProAxsis to showcase ProteaseTag® abstracts at 2017 North American Cystic Fibrosis Conference - ProAxsis